A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients With Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Trial Profile

A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients With Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms PROSPER RCC
  • Most Recent Events

    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 10 Feb 2018 Trial design presented at the 2018 Genitourinary Cancers Symposium
    • 11 Jan 2018 Planned End Date changed from 31 Jul 2022 to 30 Nov 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top